ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.498,38
0,32%
S&P 500
5.187,07
-0,01%
Dow Jones
39.046,10
0,42%
Euro vs US Dollar
1,07455
-0,04%
Bitcoin
62.320,00
-0,03%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Ligand Pharmaceuticals Incorporated (LGND)

  7. Ligand Pharmaceuticals Incorporated (LGND) News

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LGND
DatumZeitQuelleÜberschriftSymbolFirma
07/03/202419h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/03/202423h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/03/202400h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202422h09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202422h49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202400h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
28/02/202423h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
27/02/202413h24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202402h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202402h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202402h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/02/202402h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
14/02/202412h26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
13/02/202421h39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
13/02/202401h42Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
11/01/202401h30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/01/202423h40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
04/01/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
04/01/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/12/202321h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/12/202321h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/12/202314h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/12/202314h20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
28/11/202315h01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
10/11/202303h48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/11/202323h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
 Showing the most relevant articles for your search:NASDAQ:LGND

Kürzlich von Ihnen besucht

COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
AMEX
XLV
Health Care Select Sector
NYSE
KO
Coca Cola
CCOM
SILVER
SILVER
NASDAQ
AAPL
Apple
FX
EURJPY
Euro vs Yen
NYSE
NKE
Nike
FX
EURUSD
Euro vs US Dollar
CCOM
US30
US 30
DBI
MDAX
MDAX
FX
EURGBP
Euro vs Sterling
TG
RHM
Rheinmetall
AMEX
XLF
Financial Select Sector
CCOM
US100
US Tech 100
NASDAQ
MSFT
Microsoft
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten